Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study

E. Gobbini, R. Chiari, P. Pizzutillo, P. Bordi, L. Ghilardi, S. Pilotto, G. Osman, F. Cappuzzo, F. Cecere, F. Riccardi, V. Scotti, O. Martelli, G. Borra, E. Maiello, A. Rossi, P. Graziano, V. Gregorc, C. Casartelli, C. Sergi, A. Del ConteA. Delmonte, C. Bareggi, D. Cortinovis, P. Rizzo, F. Tabbò, G. Rossi, E. Bria, D. Galetta, M. Tiseo, M. Di Maio, S. Novello

Research output: Contribution to journalArticle

Abstract

Purpose: Anaplastic lymphoma kinase (ALK) rearrangement confers sensitivity to ALK inhibitors (ALKis) in non-small-cell lung cancer (NSCLC). Although several drugs provided an impressive outcome benefit, the most effective sequential strategy is still unknown. We describe outcomes of real-life patients according to the treatment strategy received. Patients: We retrospectively collected 290 ALK rearranged advanced NSCLC diagnosed between 2011 and 2017 in 23 Italian institutions. Results: After a median follow-up of 26 months, PFS for crizotinib and a new generation ALKis were 9.4 [CI 95% 7.9–11.2] and 11.1 months [CI 95% 9.2–13.8], respectively, while TTF were 10.2 [CI 95% 8.5–12.6] and 11.9 months [CI 95% 9.7–17.4], respectively, being consistent across the different settings. The composed outcomes (the sum of PFS or TTF) in patients treated with crizotinib followed by a new generation ALKis were 27.8 months [CI 95% 24.3–33.7] in PFS and 30.4 months [CI 95% 24.7–34.9] in TTF. The median OS from the diagnosis of advanced disease was 39 months [CI 95% 31.8–54.5]. Patients receiving crizotinib followed by a new generation ALKis showed a higher median OS [57 months (CI 95% 42.0–73.8)] compared to those that did not receive crizotinib [38 months (CI 95% 18.6–NR)] and those who performed only crizotinib as target agent [15 months (CI 95% 11.3–34.0)] (P < 0.0001). Conclusion: The sequential administration of crizotinib and a new generation ALKis provided a remarkable clinical benefit in this real-life population, being an interesting option to consider in selected patients.

Original languageEnglish
JournalClinical and Translational Oncology
DOIs
Publication statusAccepted/In press - Jan 1 2019

Fingerprint

Non-Small Cell Lung Carcinoma
Retrospective Studies
Therapeutics
crizotinib
anaplastic lymphoma kinase
Pharmaceutical Preparations
Population

Keywords

  • ALK inhibitors
  • Lung cancer
  • Sequence

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients : an Italian retrospective study. / Gobbini, E.; Chiari, R.; Pizzutillo, P.; Bordi, P.; Ghilardi, L.; Pilotto, S.; Osman, G.; Cappuzzo, F.; Cecere, F.; Riccardi, F.; Scotti, V.; Martelli, O.; Borra, G.; Maiello, E.; Rossi, A.; Graziano, P.; Gregorc, V.; Casartelli, C.; Sergi, C.; Del Conte, A.; Delmonte, A.; Bareggi, C.; Cortinovis, D.; Rizzo, P.; Tabbò, F.; Rossi, G.; Bria, E.; Galetta, D.; Tiseo, M.; Di Maio, M.; Novello, S.

In: Clinical and Translational Oncology, 01.01.2019.

Research output: Contribution to journalArticle

Gobbini, E, Chiari, R, Pizzutillo, P, Bordi, P, Ghilardi, L, Pilotto, S, Osman, G, Cappuzzo, F, Cecere, F, Riccardi, F, Scotti, V, Martelli, O, Borra, G, Maiello, E, Rossi, A, Graziano, P, Gregorc, V, Casartelli, C, Sergi, C, Del Conte, A, Delmonte, A, Bareggi, C, Cortinovis, D, Rizzo, P, Tabbò, F, Rossi, G, Bria, E, Galetta, D, Tiseo, M, Di Maio, M & Novello, S 2019, 'Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study', Clinical and Translational Oncology. https://doi.org/10.1007/s12094-019-02222-8
Gobbini, E. ; Chiari, R. ; Pizzutillo, P. ; Bordi, P. ; Ghilardi, L. ; Pilotto, S. ; Osman, G. ; Cappuzzo, F. ; Cecere, F. ; Riccardi, F. ; Scotti, V. ; Martelli, O. ; Borra, G. ; Maiello, E. ; Rossi, A. ; Graziano, P. ; Gregorc, V. ; Casartelli, C. ; Sergi, C. ; Del Conte, A. ; Delmonte, A. ; Bareggi, C. ; Cortinovis, D. ; Rizzo, P. ; Tabbò, F. ; Rossi, G. ; Bria, E. ; Galetta, D. ; Tiseo, M. ; Di Maio, M. ; Novello, S. / Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients : an Italian retrospective study. In: Clinical and Translational Oncology. 2019.
@article{76ad20ee9de6458187a41f77f7939f7d,
title = "Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study",
abstract = "Purpose: Anaplastic lymphoma kinase (ALK) rearrangement confers sensitivity to ALK inhibitors (ALKis) in non-small-cell lung cancer (NSCLC). Although several drugs provided an impressive outcome benefit, the most effective sequential strategy is still unknown. We describe outcomes of real-life patients according to the treatment strategy received. Patients: We retrospectively collected 290 ALK rearranged advanced NSCLC diagnosed between 2011 and 2017 in 23 Italian institutions. Results: After a median follow-up of 26 months, PFS for crizotinib and a new generation ALKis were 9.4 [CI 95{\%} 7.9–11.2] and 11.1 months [CI 95{\%} 9.2–13.8], respectively, while TTF were 10.2 [CI 95{\%} 8.5–12.6] and 11.9 months [CI 95{\%} 9.7–17.4], respectively, being consistent across the different settings. The composed outcomes (the sum of PFS or TTF) in patients treated with crizotinib followed by a new generation ALKis were 27.8 months [CI 95{\%} 24.3–33.7] in PFS and 30.4 months [CI 95{\%} 24.7–34.9] in TTF. The median OS from the diagnosis of advanced disease was 39 months [CI 95{\%} 31.8–54.5]. Patients receiving crizotinib followed by a new generation ALKis showed a higher median OS [57 months (CI 95{\%} 42.0–73.8)] compared to those that did not receive crizotinib [38 months (CI 95{\%} 18.6–NR)] and those who performed only crizotinib as target agent [15 months (CI 95{\%} 11.3–34.0)] (P < 0.0001). Conclusion: The sequential administration of crizotinib and a new generation ALKis provided a remarkable clinical benefit in this real-life population, being an interesting option to consider in selected patients.",
keywords = "ALK inhibitors, Lung cancer, Sequence",
author = "E. Gobbini and R. Chiari and P. Pizzutillo and P. Bordi and L. Ghilardi and S. Pilotto and G. Osman and F. Cappuzzo and F. Cecere and F. Riccardi and V. Scotti and O. Martelli and G. Borra and E. Maiello and A. Rossi and P. Graziano and V. Gregorc and C. Casartelli and C. Sergi and {Del Conte}, A. and A. Delmonte and C. Bareggi and D. Cortinovis and P. Rizzo and F. Tabb{\`o} and G. Rossi and E. Bria and D. Galetta and M. Tiseo and {Di Maio}, M. and S. Novello",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s12094-019-02222-8",
language = "English",
journal = "Clinical and Translational Oncology",
issn = "1699-048X",
publisher = "Springer-Verlag Italia",

}

TY - JOUR

T1 - Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients

T2 - an Italian retrospective study

AU - Gobbini, E.

AU - Chiari, R.

AU - Pizzutillo, P.

AU - Bordi, P.

AU - Ghilardi, L.

AU - Pilotto, S.

AU - Osman, G.

AU - Cappuzzo, F.

AU - Cecere, F.

AU - Riccardi, F.

AU - Scotti, V.

AU - Martelli, O.

AU - Borra, G.

AU - Maiello, E.

AU - Rossi, A.

AU - Graziano, P.

AU - Gregorc, V.

AU - Casartelli, C.

AU - Sergi, C.

AU - Del Conte, A.

AU - Delmonte, A.

AU - Bareggi, C.

AU - Cortinovis, D.

AU - Rizzo, P.

AU - Tabbò, F.

AU - Rossi, G.

AU - Bria, E.

AU - Galetta, D.

AU - Tiseo, M.

AU - Di Maio, M.

AU - Novello, S.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Purpose: Anaplastic lymphoma kinase (ALK) rearrangement confers sensitivity to ALK inhibitors (ALKis) in non-small-cell lung cancer (NSCLC). Although several drugs provided an impressive outcome benefit, the most effective sequential strategy is still unknown. We describe outcomes of real-life patients according to the treatment strategy received. Patients: We retrospectively collected 290 ALK rearranged advanced NSCLC diagnosed between 2011 and 2017 in 23 Italian institutions. Results: After a median follow-up of 26 months, PFS for crizotinib and a new generation ALKis were 9.4 [CI 95% 7.9–11.2] and 11.1 months [CI 95% 9.2–13.8], respectively, while TTF were 10.2 [CI 95% 8.5–12.6] and 11.9 months [CI 95% 9.7–17.4], respectively, being consistent across the different settings. The composed outcomes (the sum of PFS or TTF) in patients treated with crizotinib followed by a new generation ALKis were 27.8 months [CI 95% 24.3–33.7] in PFS and 30.4 months [CI 95% 24.7–34.9] in TTF. The median OS from the diagnosis of advanced disease was 39 months [CI 95% 31.8–54.5]. Patients receiving crizotinib followed by a new generation ALKis showed a higher median OS [57 months (CI 95% 42.0–73.8)] compared to those that did not receive crizotinib [38 months (CI 95% 18.6–NR)] and those who performed only crizotinib as target agent [15 months (CI 95% 11.3–34.0)] (P < 0.0001). Conclusion: The sequential administration of crizotinib and a new generation ALKis provided a remarkable clinical benefit in this real-life population, being an interesting option to consider in selected patients.

AB - Purpose: Anaplastic lymphoma kinase (ALK) rearrangement confers sensitivity to ALK inhibitors (ALKis) in non-small-cell lung cancer (NSCLC). Although several drugs provided an impressive outcome benefit, the most effective sequential strategy is still unknown. We describe outcomes of real-life patients according to the treatment strategy received. Patients: We retrospectively collected 290 ALK rearranged advanced NSCLC diagnosed between 2011 and 2017 in 23 Italian institutions. Results: After a median follow-up of 26 months, PFS for crizotinib and a new generation ALKis were 9.4 [CI 95% 7.9–11.2] and 11.1 months [CI 95% 9.2–13.8], respectively, while TTF were 10.2 [CI 95% 8.5–12.6] and 11.9 months [CI 95% 9.7–17.4], respectively, being consistent across the different settings. The composed outcomes (the sum of PFS or TTF) in patients treated with crizotinib followed by a new generation ALKis were 27.8 months [CI 95% 24.3–33.7] in PFS and 30.4 months [CI 95% 24.7–34.9] in TTF. The median OS from the diagnosis of advanced disease was 39 months [CI 95% 31.8–54.5]. Patients receiving crizotinib followed by a new generation ALKis showed a higher median OS [57 months (CI 95% 42.0–73.8)] compared to those that did not receive crizotinib [38 months (CI 95% 18.6–NR)] and those who performed only crizotinib as target agent [15 months (CI 95% 11.3–34.0)] (P < 0.0001). Conclusion: The sequential administration of crizotinib and a new generation ALKis provided a remarkable clinical benefit in this real-life population, being an interesting option to consider in selected patients.

KW - ALK inhibitors

KW - Lung cancer

KW - Sequence

UR - http://www.scopus.com/inward/record.url?scp=85074765843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074765843&partnerID=8YFLogxK

U2 - 10.1007/s12094-019-02222-8

DO - 10.1007/s12094-019-02222-8

M3 - Article

C2 - 31630357

AN - SCOPUS:85074765843

JO - Clinical and Translational Oncology

JF - Clinical and Translational Oncology

SN - 1699-048X

ER -